Updated Phase 2 data show a 74% progression-free survival rate at 16 months in the target population for iSCIB1+ added to ipilimumab plus nivolumab, compared with 50% PFS at 11.5 months reported for the checkpoint inhibitor doublet alone. Scancell also cites an interim 24 percentage-point PFS improvement versus real-world standard of care and historical benchmarks. These are cross-trial comparisons from an open-label study but provide the topline signal underpinning next steps.
The core development is FDA clearance of an IND for a registrational Phase 3 trial of iSCIB1+ in advanced melanoma with progression-free survival as the agreed surrogate endpoint. The program advances off the 140-patient SCOPE Phase 2 study evaluating SCIB1/iSCIB1+ with nivolumab plus ipilimumab in previously untreated, unresectable stage IIIB/IV melanoma. Scancell has selected iSCIB1+—a needle-free intramuscular DNA Immunobody—for the Phase 3 and plans to enrich for patients based on a selection marker within defined HLA alleles that the company says cover roughly 80% of melanoma patients. The Phase 2 signal appeared consistent across key subgroups, including PD-L1 low, BRAF wild-type, and those with prior checkpoint exposure.
Strategically, securing PFS as the registrational endpoint suggests an attempt to accelerate readout and de-risk overall survival dependencies in a tumor type where SOC PD-1–based regimens already demonstrate long-term benefit. The enrichment strategy is a calculated bid to lift effect size and reduce sample size, trading broader generalizability for a cleaner efficacy signal in a preselected immunologic context. The tension is that the evidence base still leans on historical and real-world comparators rather than a randomized contemporaneous control, and melanoma first-line practice is evolving. Many U.S. centers increasingly deploy nivolumab plus relatlimab in place of ipilimumab plus nivolumab for safety and operational reasons, so the control arm choice will be consequential both scientifically and commercially.
Operationally, the Phase 3 will add biomarker logistics and device training to already complex checkpoint combination management. Sites will need upfront HLA typing, likely via centralized testing, and capacity to coordinate vaccine dosing alongside immune-related adverse event monitoring from the doublet backbone. For CROs and vendors, that means tighter screening workflows, timelines sensitive to genotyping turnaround, and potential procurement and calibration of needle-free delivery systems. If the selection marker is implemented as an inclusion criterion rather than a stratification factor, screen fail rates could rise, affecting enrollment velocity and site economics. Regulators will be watching how PFS correlates with OS in an add-on setting and whether the HLA-enriched design maintains external validity across diverse U.S. and ex-U.S. populations.
Next, attention turns to the Phase 3 protocol: control regimen selection (ipi+nivo versus PD-1/LAG-3), powering assumptions based on enriched PFS, and event-driven timelines. Clear articulation of the selection marker and its testing pathway will be critical to site feasibility and any companion diagnostic discussions. From a manufacturing standpoint, scaling DNA plasmid supply and ensuring consistent device availability across geographies are non-trivial execution risks. Funding remains an explicit variable; partnering could influence footprint, speed, and control-arm negotiations. The key watch items are whether the Phase 3 adopts a contemporary control aligned with current prescribing patterns, how quickly PFS events accrue under enrichment, and whether safety remains manageable when layering a vaccine onto a toxic checkpoint backbone. If PFS holds and OS trends emerge, the path to approval tightens; if not, the reliance on historical benchmarks will become a liability.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
